COVID-19 vaccines: Efficacy varies in different scenarios

Daniel Fowler
January 30, 2021

Defeating the scourge that has killed more than 2 million people worldwide will require vaccinating billions, and the shots being rolled out in different countries so far all require two doses a few weeks apart for full protection.

A spokesperson of the company responded that latest analysis of clinical trial data for the vaccine "support efficacy in the over 65 years age group", and added they are "awaiting a regulatory decision by the European Union medicines regulator", CNN reported.

"Right now, any protection and additional vaccine is great".

J&J said its vaccine works consistently in a broad range of people: A third of participants were over age 60, and more than 40% had other illnesses putting them at risk of severe COVID-19, including obesity, diabetes and HIV.

Johnson & Johnson has been developing a single-dose vaccine for COVID-19, which has an efficacy rate of approximately 72 percent, potentially bringing another provider into the mix as vaccines for the virus have become a valuable and scarce commodity.

Public health officials have been counting on the J&J vaccine to increase much-needed supply and simplify the US immunization campaign.

There were also positive trial results yesterday from Johnson and Johnson's vaccine, which was found to be 66% effective.

"A one-shot vaccine is considered by the World Health Organisation to be the best option in pandemic settings, enhancing access, distribution and compliance".

The company is expected to have approximately seven million doses ready if the FDA authorizes the vaccine, with almost 30 million ready by April.

Rare Botticelli portrait sells for record $92M at USA auction
Sotheby's senior vice president Christopher Apostle described Young Man Holding a Roundel as a "masterpiece" ahead of the auction .

Approval of the Johnson & Johnson vaccine has been referred to by public health officials as a "game changer" because it would be the first of its kind that didn't require a second dose.

Janssen, a pharmaceutical company owned by Johnson & Johnson, is also investigating whether giving two doses will give either stronger or longer-lasting protection.

While some of these values aren't quite as impressive as other jabs now in use, the Jenssen vaccine requires only one dose.

Other points raised about the new cases reported today show that 667 are men / 742 are women, 59% are under 45 years of age with the median age is 39 years old.

Novavax on Thursday released initial results from a United Kingdom trial showing its vaccine to be 89.3% effective in preventing COVID-19, and was almost as effective in protecting against the more highly contagious variant of the coronavirus first discovered in the UK.

The state's latest list of COVID-19 vaccination sites, released at noon on Friday, includes more than 100 locations across MA.

"We're not in charge of (vaccines), and we have no knowledge of the efficacy against strains or how it compares to Pfizer or Moderna", he said this week.

Coronavirus has infected at least 556,109 MI residents since March, including in 14,491 cases that were fatal.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER